249 related articles for article (PubMed ID: 23637922)
1. A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.
Manish M; Rahi A; Kaur M; Bhatnagar R; Singh S
PLoS One; 2013; 8(4):e61885. PubMed ID: 23637922
[TBL] [Abstract][Full Text] [Related]
2. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against
Majumder S; Das S; Somani VK; Makam SS; Kingston JJ; Bhatnagar R
Front Immunol; 2019; 10():498. PubMed ID: 30941133
[TBL] [Abstract][Full Text] [Related]
3. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
[TBL] [Abstract][Full Text] [Related]
4. Trimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.
Malik A; Gupta M; Mani R; Gogoi H; Bhatnagar R
Front Immunol; 2018; 9():562. PubMed ID: 29616046
[TBL] [Abstract][Full Text] [Related]
5. A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis.
Majumder S; Das S; Somani V; Makam SS; Joseph KJ; Bhatnagar R
Sci Rep; 2018 May; 8(1):7242. PubMed ID: 29740033
[TBL] [Abstract][Full Text] [Related]
6. A niosome formulation modulates the Th1/Th2 bias immune response in mice and also provides protection against anthrax spore challenge.
Gogoi H; Mani R; Bhatnagar R
Int J Nanomedicine; 2018; 13():7427-7440. PubMed ID: 30532531
[TBL] [Abstract][Full Text] [Related]
7. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
[No Abstract] [Full Text] [Related]
8. Development of a novel chimeric PA-LF antigen of Bacillus anthracis, its immunological characterization and evaluation as a future vaccine candidate in mouse model.
Varshney A; Kumar M; Nagar DP; Pal V; Goel AK
Biologicals; 2019 Sep; 61():38-43. PubMed ID: 31416791
[TBL] [Abstract][Full Text] [Related]
9. Preparation and Characterization of PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation.
Manish M; Bhatnagar R; Singh S
Methods Mol Biol; 2016; 1404():669-681. PubMed ID: 27076329
[TBL] [Abstract][Full Text] [Related]
10. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
Welkos S; Little S; Friedlander A; Fritz D; Fellows P
Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
[TBL] [Abstract][Full Text] [Related]
11. Intranasal administration of dry powder anthrax vaccine provides protection against lethal aerosol spore challenge.
Huang J; Mikszta JA; Ferriter MS; Jiang G; Harvey NG; Dyas B; Roy CJ; Ulrich RG; Sullivan VJ
Hum Vaccin; 2007; 3(3):90-3. PubMed ID: 17375001
[TBL] [Abstract][Full Text] [Related]
12. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R
Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775
[TBL] [Abstract][Full Text] [Related]
13. BA3338, a surface layer homology domain possessing protein augments immune response and protection efficacy of protective antigen against Bacillus anthracis in mouse model.
Kumar M; Puranik N; Varshney A; Tripathi N; Pal V; Goel AK
J Appl Microbiol; 2020 Aug; 129(2):443-452. PubMed ID: 32118336
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
15. Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.
Koehler SM; Buyuk F; Celebi O; Demiraslan H; Doganay M; Sahin M; Moehring J; Ndumnego OC; Otlu S; van Heerden H; Beyer W
BMC Vet Res; 2017 Jul; 13(1):220. PubMed ID: 28701192
[TBL] [Abstract][Full Text] [Related]
16. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice.
Ribeiro S; Rijpkema SG; Durrani Z; Florence AT
Int J Pharm; 2007 Mar; 331(2):228-32. PubMed ID: 17258876
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of the humoral and cellular immunity induced by live A16R attenuated spore and AVA-like anthrax vaccine in mice.
Lv J; Zhang YY; Lu X; Zhang H; Wei L; Gao J; Hu B; Hu WW; Hu DZ; Jia N; Feng X
Biologicals; 2017 Mar; 46():130-138. PubMed ID: 28215694
[TBL] [Abstract][Full Text] [Related]
18. Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids.
Enkhtuya J; Kawamoto K; Kobayashi Y; Uchida I; Rana N; Makino SI
Microbiology (Reading); 2006 Oct; 152(Pt 10):3103-3110. PubMed ID: 17005989
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
Park YS; Lee JH; Hung CF; Wu TC; Kim TW
Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
[TBL] [Abstract][Full Text] [Related]
20. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
